Thursday's cash session reversed much of Wednesday's damage: the S&P 500 rose 1.14%, Nasdaq 1.69%, Dow 0.61% and Russell 2000 0.55%, while VIX fell to 15.44. Treasury's official curve put the 2Y at 4.67% and 10Y at 4.94%, both 7 bp lower than Wednesday. This is supportive, but the level of yields remains restrictive. Yahoo markets · Treasury
The BOJ raised its policy rate to 1.25% from 1.00% by a 7–2 vote, a 31-year high. Despite that tightening, Japan, Korea, Hong Kong and mainland China traded higher; the yen weakened versus the dollar in Yahoo's early snapshot. The divergence suggests the move was well anticipated, not risk-free. BOJ decision · Reuters
AMD gained 6.36%, NVDA 2.54%, and quantum pure plays rose 5.5%–9.5%. IonQ also released a concrete hybrid-workflow result: 5.9%–14.6% runtime improvements across tested engineering models. Useful evidence, but not proof of scalable commercial economics; high-beta rallies after drawdowns remain vulnerable. Nasdaq API · IonQ IR
| Asset | Level | Move / session | Read-through |
|---|---|---|---|
| S&P 500 | 7,637.76 | +1.14% | Thursday cash close; broad relief after post-Fed selloff. |
| Nasdaq Composite | 26,418.30 | +1.69% | Technology leadership; NVDA +2.54%, AMD +6.36%. |
| Dow / Russell 2000 | 51,778.04 / 2,874.63 | +0.61% / +0.55% | Positive breadth signal, although small caps lagged mega-cap tech. |
| VIX | 15.44 | −12.82% | Volatility normalization, not protection against event gaps. |
| U.S. 2Y / 10Y | 4.67% / 4.94% | both −7 bp | Official Sept. 17 par curve; still a high discount-rate environment. |
| Dollar index | 100.29 | +0.04% | Firm after Fed hike; USD/JPY 157.12, +0.75% in early trade. |
| WTI / Brent | $100.75 / $103.51 | −1.14% / −1.25% | Inflation relief at the margin; absolute prices remain a macro risk. |
| Gold | $4,428.40 | +0.65% | Geopolitical/inflation hedge demand persists despite firm dollar. |
| Nikkei 225 | 65,045.62 | +1.42% | Yahoo early/near-close snapshot; BOJ raised rates to 1.25%. |
| KOSPI | 6,877.63 | +2.42% | Strongest major Asian move in Yahoo snapshot. |
| Hang Seng / Shanghai | 24,826.83 / 3,909.09 | +0.90% / +0.86% | Still trading near cutoff; not final closes. |
| STOXX 600 / DAX / FTSE | 642.60 / 25,716.71 / 10,816.14 | prior close +0.86% / +0.70% / +1.19% | Europe had not opened at 08:30 Italy; these are Thursday closes. |
| S&P / Nasdaq Dec. futures | 7,727.25 / 29,878.50 | +0.26% / +0.46% | CNBC delayed quotes at 02:21 EDT; positive but modest. |
Session labels matter: U.S. equity and VIX figures are Sept. 17 closes; Treasury yields are the official Sept. 17 curve; commodities, FX, Asian markets and U.S. futures are early Sept. 18 indications. Cross-checks: CNN Markets, Yahoo Markets, CNBC S&P futures, CNBC Nasdaq futures.
Fewer ideas are intentional. Scores are comparative research judgments, not probabilities. Confidence measures evidence quality; risk is higher when riskier. Entries require live confirmation.
NASDAQ · Mega-cap · Medium/high risk · Horizon: 1–4 week swing and 3–12+ month investment
Thesis/catalyst: Thursday's 2.54% gain to $219.34 reclaims the prior report's ~$218.5 confirmation area, while the CUDA-Q release reinforces NVIDIA's optionality beyond GPUs. Core AI demand remains the principal thesis. Counterargument: one rebound does not erase 4.94% 10Y yields, China/export constraints, customer concentration or AI-capex financing risk.
NYSE · Mega-cap pharma · Medium risk · Horizon: 3–12+ months
Thesis/catalyst: a deep commercial and investigational metabolic portfolio, with multiple EASD readouts in 10–14 days. Counterargument: $1,152.44 reflects substantial expectations; retatrutide remains investigational and efficacy headlines must be judged with discontinuations, GI events, dysesthesia and full statistics.
NASDAQ · Large-cap/high-beta AI infrastructure · Very high risk · Horizon: day trade and 1–4 weeks
Thesis: $79.88 and −4.16% on ~79.5m shares was stark relative weakness while Nasdaq rose 1.69%; the setup is exposed to capex funding, customer concentration and high long-duration yields. Counterargument: AI infrastructure demand and contract headlines can trigger violent rebounds.
NASDAQ · Small-cap quantum/photonics · Extreme risk · Horizon: 1–4 weeks
Thesis: the 5.50% rebound to $8.44 is sector-beta evidence, not a disclosed commercial inflection. The category's valuations and cash burn remain highly sensitive to rates and narrative reversals. Counterargument: quantum announcements and momentum can overwhelm fundamentals for extended periods.
| Rank / ticker | Classification & horizon | Evidence / trigger | Invalidation & key risk | C / R / O |
|---|---|---|---|---|
| 1 AMD NASDAQ, mega-cap, high beta | Bullish watch Day / 1–4 weeks | $545.09, +6.36%. Require a non-gap hold above $540 and semis outperforming; avoid chasing a vertical open. Quote | Close below $512.50 (prior close) erases the breakout; valuation, competition and AI-capex risk. | 70 / 74 / 73 |
| 2 VRT NYSE, large-cap AI power/cooling | Reversal watch 1–4 weeks / 3–12 months | $241.49, +0.87%; require reclaim of ~$259. UIG can expand addressable market, but acquisition execution matters. | New reaction low; data-center capex, integration, earnout and multiple risk. IR | 71 / 72 / 68 |
| 3 IONQ NYSE, speculative quantum | Milestone watch 1–4 weeks / 3–12+ months | $40.34, +9.50%; hybrid results are constructive. Require hold above $40 and proof that research converts to orders/revenue. | Close below $36.84; cash burn, dilution, integration and roadmap risk. Research release | 72 / 91 / 66 |
| 4 VKTX NASDAQ, clinical-stage small/mid-cap biotech | Binary watch 3–12+ months | $29.36, −0.54%. Wait for maintenance data/full methods or oral Phase 3 initiation; prior oral Phase 2 reached up to 12.2% mean loss at 13 weeks. | Clinical/tolerability miss or financing pressure; event gaps can be severe. Cash $502m at June 30. IR | 64 / 89 / 65 |
| 5 AVGO NASDAQ, mega-cap semis/software | Recovery watch 1–4 weeks | $347.30, +2.29%; require a sustained close above $360 rather than chasing the bounce. | Loss of $339.51 prior close; custom-silicon concentration, valuation and high-rate risk. Quote | 72 / 66 / 67 |
Bias: cautiously long if positive futures survive the cash open and semis lead with broad participation; avoid chasing AMD/quantum gaps. Biggest risk: expiry flows, oil/geopolitical headlines and a yield reversal. Invalidation: S&P futures lose their prior close while 10Y returns above 5%.
Bias: quality momentum over speculative beta—NVDA only on a $219–224 hold/reclaim; CRWV relative weakness is an avoid. Biggest risk: PCE/jobs data revive a faster hiking path. Invalidation: falling breadth and VIX reclaim above Thursday's 17.71 prior close.
Bias: stage entries in proven AI platforms and diversified metabolic leaders; treat quantum and clinical-stage biotech as small speculative sleeves, not core equivalents. Biggest risk: capex/clinical economics fail to justify valuation. Invalidation: sustained estimate cuts, financing stress or adverse regulatory/benefit-risk evidence.